A Randomized Phase 2 Trial Of Anlotinib Plus Docetaxel Vs Docetaxel As 2nd-Line Therapy For Egfr-Negative Nsclc (Alter-L018)
JOURNAL OF THORACIC ONCOLOGY（2021）
关键词
non-small cell lung cancer, second-line, Anlotinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要